Sunday, September 25, 2016 |Latest E-book
You are here:
gsk
#

gsk

Articles

Hunt for AIDS cure accelerates as GSK and US experts link up

May 11, 2015

Hunt for AIDS cure accelerates as GSK and US experts link up

Britain's GlaxoSmithKline , which decided last week to retain rather than float off its HIV drugs business, is to collaborate with U.S. scientists in developing a cure for AIDS. #US #NewsTracker #HIV #Drugs #AIDS #Britain #gsk #cure
Sun Pharma buys GSK's opiates biz in Australia: All you need to know

Mar 03, 2015

Sun Pharma buys GSK's opiates biz in Australia: All you need to know

Drug major Sun Pharma will acquire GlaxoSmithKline's Opiates business in Australia for an undisclosed amount to strengthen its pain management portfolio. Both companies said they expect to close the deal by August. #Australia #Sun Pharma #Pharma #gsk #Tasmania #opiates
China fines drugmaker GSK record $489 mn in bribery case, sentences executives

Sep 19, 2014

China fines drugmaker GSK record $489 mn in bribery case, sentences executives

China has fined GlaxoSmithKline Plc a record 3 billion yuan ($488.8 million) for paying bribes to doctors to use its drugs, the British company said on Friday, drawing to a close a corruption probe that rocked the pharmaceutical sector in China. #China #Corruption #Bribery #gsk #GlaxoSmithKline Plc
US probe: GSK's China unit faces more than just bribery charges

Sep 09, 2014

US probe: GSK's China unit faces more than just bribery charges

GSK confirmed it had conducted an investigation into procurement practices in consumer healthcare in China, but said it did not find any "unethical conduct".
#China #Corruption #Bribery #US #Healthcare #Sales #gsk #probe
Lupin, US firms plan bids for range of GSK drugs to be auctioned

Jul 22, 2014

Lupin, US firms plan bids for range of GSK drugs to be auctioned

Assuming a multiple of between two and three times those sales, the assets on the block could fetch between $3.5 billion and $5.0 billion.
#Sun Pharma #Drugs #Lupin #Ranbaxy #Sanofi #Pharma #GlaxoSmithKline #gsk #Novartis #Abbott #Aspen
Sameer Goel appointed as drug co Cipla's India chief

Jan 20, 2014

Sameer Goel appointed as drug co Cipla's India chief

Goel, who comes to Cipla from GlaxoSmithKline (GSK), will be reporting to company's Managing Director and Global CEO Subhanu Saxena.

#Cipla #CompanyWatch #GlaxoSmithKline #gsk #Sameer Goel
FIPB clears GSK's Rs 6,400 cr FDI proposal to hike stake in India

Jan 13, 2014

FIPB clears GSK's Rs 6,400 cr FDI proposal to hike stake in India

The Singapore subsidiary of the UK-based GlaxoSmithKline plans to buy 24.33 percent stake or 2.06 crore equity shares in GlaxoSmithKline Pharmaceuticals Ltd through an open offer. #NewsTracker #FDI #FIPB #Daiichi Sankyo #GlaxoSmithKline #gsk #Mylan Inc. #Arvind Mayaram #Agila Specialities #Strides Acrolab #Piramal Health Care
Pharma sector registers single digit growth in 2013; regulators increase scrutiny

Dec 29, 2013

Pharma sector registers single digit growth in 2013; regulators increase scrutiny

The Indian pharma sector, estimated to be around Rs 1.5 lakh crore, recorded single digit growth for the first time in several years on account of deeper price cuts under pricing policy and selective boycott of companies by the retailers. #FDI #Cipla #Sun Pharmaceuticals #Wockhardt #Ranbaxy #Pharma #Torrent Pharmaceuticals #WTO #Biocon #gsk #Pfizer #Piramal Enterprises #USFDA #Novartis #Dr. Reddy #RearView2013 #Elder #IPAB #Zydus #Cadilla
GSK, Pepsi among FMCG majors who bet big on India despite slowdown

Dec 25, 2013

GSK, Pepsi among FMCG majors who bet big on India despite slowdown

Unilever, GlaxoSmithKline and PepsiCo made big bang announcements during the year as they decided to enhance their play in the "strategic and emerging" Indian market. #Nokia #FMCG #Unilever #Coca-Cola #Nestle #HUL #Marico #Pepsi #gsk #Godrej #Indira Nooyi #RearView2013
GSK to stop paying doctors to promote products, end sales reps' targets

Dec 17, 2013

GSK to stop paying doctors to promote products, end sales reps' targets

The initiative represents a bid by Britain's biggest drugmaker to get ahead of its critics by addressing potential conflicts of interest that could put commercial interests ahead of the best outcome for patients.

#WhyNow #Pharma #GlaxoSmithKline #gsk #doctor payments